DarioHealth Corp.
corporate_fare Company Profile
DarioHealth Corp. (NASDAQ:DRIO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for DRIO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for DRIO spans 10-Q, 424B5, 8-K, S-3.
Recent high-impact activity:
- Dario Lands WebMD Distribution Deal Reaching 65 Million Covered Lives
- DarioHealth Posts $5.3M Q3 Revenue as Covenant Breach Looms
- DarioHealth Q3 Loss Narrows to $8.8M; Covenant Cured With $22.8M of Offering Proceeds
- DarioHealth Lands 1.5M-Covered-Lives Contract with Major NJ Health Plan
- DarioHealth Q2 Revenue Misses by 12%, Pharma Exit Weighs on Top Line
Financial Snapshot
Short Interest & Short Volume
1.21 days to coverFINRA reported short interest of 114,624 shares in DRIO as of the October 30, 2026 settlement, a 41.1% increase from the prior period — about 1.2 days to cover at its recent average daily volume. On November 20, 2026, 24.2% of DRIO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
High riskFiling-implied dilution signals for DRIO, detected from its recent SEC filings · based on capital-structure filings through 2026-07-22.
$23.5M Registered Direct Offering Priced · Significant Dilution to Existing Holders
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →